Platinum based chemotherapy

DRUG15 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, GlaxoSmithKline, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanghai Zhongshan Hospital, Jun-Lin Yi, MD

Conditions

Carcinoma, Non-Small-Cell LungChemoradiationChemotherapy EffectEsophageal CancerEsophagogastric Juction CancerEsophagogastric Junction CancerEsophagus CancerHPV-Related Carcinoma

Phase 1

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

TerminatedNCT03663166

H. Lee Moffitt Cancer Center and Research InstituteCarcinoma, Non-Small-Cell Lung

Start: 2018-11-20End: 2021-10-22Updated: 2023-02-15

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Shanghai Zhongshan HospitalNon-Small Cell Lung Cancer

Start: 2021-09-01End: 2022-12-30Target: 20Updated: 2021-08-17

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Active, not recruitingNCT06236425

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck

Start: 2024-03-14End: 2026-08-01Updated: 2026-04-01

Phase 2

Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)

Jun-Lin Yi, MDHead and Neck Squamous Cell Carcinoma, Immunotherapy, Metastases +1

Start: 2021-12-31End: 2024-12-31Target: 50Updated: 2021-11-29

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

RecruitingNCT05657873

Memorial Sloan Kettering Cancer CenterNon-small Cell Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic +2

Start: 2022-12-09End: 2026-12-09Target: 68Updated: 2026-03-27

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

Active, not recruitingNCT06234748

University of Michigan Rogel Cancer CenterHPV-Related Carcinoma, Oropharynx Cancer

Start: 2023-12-20End: 2026-07-31Updated: 2025-05-13

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

RecruitingNCT06424899

Zeng JianNon Small Cell Lung Cancer

Start: 2024-05-19End: 2027-12-31Target: 92Updated: 2024-05-22

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

RecruitingNCT06623656

Weill Medical College of Cornell UniversityCarcinoma, Non-Small-Cell Lung

Start: 2025-02-21End: 2032-01-31Target: 112Updated: 2025-10-23

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

Not yet recruitingNCT07295132

Asan Medical CenterOvarian Cancer Recurrent, Platinum Sensitive Ovarian Cancer

Start: 2025-12-15End: 2029-11-15Target: 160Updated: 2025-12-19

Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

Not yet recruitingNCT07340164

Yonsei UniversityOvarian Cancer, Ovarian Cancer Metastatic Recurrent, Ovarian Cancer (OvCa) +1

Start: 2025-12-30End: 2030-12-31Target: 116Updated: 2026-01-14

Phase 3

Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

TerminatedNCT04428333

GlaxoSmithKlineNeoplasms, Head and Neck

Start: 2020-08-12End: 2023-09-19Updated: 2024-10-09

Neoadjuvant Treatment Modalities in Esophageal Cancer

RecruitingNCT04821843

Cancer Institute and Hospital, Chinese Academy of Medical SciencesChemoradiation, Chemotherapy Effect, Esophageal Cancer +4

Start: 2002-01-01End: 2030-12-31Target: 2000Updated: 2026-01-21

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

RecruitingNCT04821778

Cancer Institute and Hospital, Chinese Academy of Medical SciencesChemoradiation, Chemotherapy Effect, Esophagogastric Junction Cancer +3

Start: 2002-01-01End: 2030-12-31Target: 2000Updated: 2026-01-21

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

RecruitingNCT06216301

NovoCure GmbHMetastatic Non-small Cell Lung Cancer

Start: 2024-07-31End: 2028-10-31Target: 734Updated: 2025-12-17

Unknown Phase

The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer

RecruitingNCT06000358

Lithuanian University of Health SciencesLung Cancer Stage IV

Start: 2023-04-01End: 2026-03-31Target: 120Updated: 2023-08-21

Related Papers

Abstract 4456: Tumor Treating Fields (TTFields) potentiate antitumor and immune responses to standard immunochemotherapy in non-small cell lung cancer models.

Cancer Research2026-04-03

A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)

BMC Cancer2025-09-02

Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study

Cancer Biology & Therapy2025-05-142 citations

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.

2025-04-23

A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).

Journal of Clinical Oncology2024-06-012 citations

LUNAR-2: Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum based chemotherapy for the treatment of metastatic non-small cell lung cancer.

Journal of Clinical Oncology2024-06-01